Pfizer to stop developing its twice-daily weight loss pill due to adverse side effects

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
More News: Health | Pfizer | Study | Weight Loss